×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ACHV – achieve life sciences, inc. - common shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ACHV
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/29
07:19 am
achv
Institutions profited after Achieve Life Sciences, Inc.'s (NASDAQ:ACHV) market cap rose US$48m last week but individual investors profited the most [Yahoo! Finance]
Medium
Report
Institutions profited after Achieve Life Sciences, Inc.'s (NASDAQ:ACHV) market cap rose US$48m last week but individual investors profited the most [Yahoo! Finance]
11/25
08:41 am
achv
Achieve Life Sciences (NASDAQ:ACHV) is now covered by analysts at Citizens Jmp. They set a "market outperform" rating and a $19.00 price target on the stock.
High
Report
Achieve Life Sciences (NASDAQ:ACHV) is now covered by analysts at Citizens Jmp. They set a "market outperform" rating and a $19.00 price target on the stock.
11/25
05:04 am
achv
Achieve Life Sciences (NASDAQ:ACHV) is now covered by analysts at Citigroup Inc.. They set an "outperform" rating on the stock.
High
Report
Achieve Life Sciences (NASDAQ:ACHV) is now covered by analysts at Citigroup Inc.. They set an "outperform" rating on the stock.
11/24
07:02 am
achv
Achieve Life Sciences (NASDAQ:ACHV) had its "strong-buy" rating reaffirmed by analysts at Raymond James Financial, Inc..
Medium
Report
Achieve Life Sciences (NASDAQ:ACHV) had its "strong-buy" rating reaffirmed by analysts at Raymond James Financial, Inc..
11/12
01:23 pm
achv
Achieve Life Sciences (NASDAQ:ACHV) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Achieve Life Sciences (NASDAQ:ACHV) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
11/10
09:37 am
achv
ACHV: FDA's CNPV Awarded for Vaping [Yahoo! Finance]
Low
Report
ACHV: FDA's CNPV Awarded for Vaping [Yahoo! Finance]
11/7
01:12 am
achv
Achieve Life Sciences (NASDAQ:ACHV) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Achieve Life Sciences (NASDAQ:ACHV) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
11/6
07:17 am
achv
Achieve Life Sciences GAAP EPS of -$0.28 misses by $0.02 [Seeking Alpha]
Low
Report
Achieve Life Sciences GAAP EPS of -$0.28 misses by $0.02 [Seeking Alpha]
Date
Time
Symbol
Company Name
Action
%Chg
11/6/2025
07:00 am
achv
achieve life sciences, inc. - common shares
MISS
Report
-4.4%
achieve life sciences, inc. - common shares
8/7/2025
07:30 am
achv
achieve life sciences, inc. - common shares
IN-LINE
Report
-4.3%
achieve life sciences, inc. - common shares
5/13/2025
07:30 am
achv
achieve life sciences, inc. - common shares
IN-LINE
Report
6.9%
achieve life sciences, inc. - common shares
3/11/2025
07:30 am
achv
achieve life sciences, inc. - common shares
MISS
Report
-5.5%
achieve life sciences, inc. - common shares
Date
Time
Symbol
Headline
Impact
11/14
08:05 pm
achv
Form SCHEDULE 13G/A ACHIEVE LIFE SCIENCES, Filed by: Alyeska Investment Group, L.P.
Low
Report
Form SCHEDULE 13G/A ACHIEVE LIFE SCIENCES, Filed by: Alyeska Investment Group, L.P.
11/14
10:55 am
achv
Form SCHEDULE 13G/A ACHIEVE LIFE SCIENCES, Filed by: Contrarian Alpha, LP
Medium
Report
Form SCHEDULE 13G/A ACHIEVE LIFE SCIENCES, Filed by: Contrarian Alpha, LP
11/6
07:16 am
achv
Form 10-Q ACHIEVE LIFE SCIENCES, For: Sep 30
Medium
Report
Form 10-Q ACHIEVE LIFE SCIENCES, For: Sep 30
11/6
07:10 am
achv
Form 8-K ACHIEVE LIFE SCIENCES, For: Nov 06
Low
Report
Form 8-K ACHIEVE LIFE SCIENCES, For: Nov 06
10/21
04:57 pm
achv
Form 3 ACHIEVE LIFE SCIENCES, For: Oct 20 Filed by: Atkisson Erik
Low
Report
Form 3 ACHIEVE LIFE SCIENCES, For: Oct 20 Filed by: Atkisson Erik
10/7
04:52 pm
achv
Form 8-K ACHIEVE LIFE SCIENCES, For: Oct 06
Medium
Report
Form 8-K ACHIEVE LIFE SCIENCES, For: Oct 06
10/3
04:38 pm
achv
Form 4 ACHIEVE LIFE SCIENCES, For: Oct 01 Filed by: Donnelly Craig
Low
Report
Form 4 ACHIEVE LIFE SCIENCES, For: Oct 01 Filed by: Donnelly Craig
9/22
04:31 pm
achv
Form 4 ACHIEVE LIFE SCIENCES, For: Sep 18 Filed by: Oki Mark K
Medium
Report
Form 4 ACHIEVE LIFE SCIENCES, For: Sep 18 Filed by: Oki Mark K
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/30
Form 8-K ACHIEVE LIFE SCIENCES, For: Apr 27
35.3%
12/9 Achieve Life Sciences Announces Completion of Meeting with the U.S. Food & Drug Administration (FDA) on Cytisinicline Smoking Cessation Phase 3 Clinical Development Program 14.3%
5/28 Form 4 ACHIEVE LIFE SCIENCES, For: May 23 Filed by: Stewart Richard Alistair 11.6%
6/11 Achieve Life Sciences Inc (NASDAQ: ACHV) had its "buy" rating re-affirmed by analysts at LADENBURG THALM/SH SH. They now have a $20.00 price target on the stock, up previously from $12.00. 9.2%
6/7 Form 3 ACHIEVE LIFE SCIENCES, For: May 30 Filed by: Armistice Capital Master Fund Ltd. 8.4%
8/12 Achieve Life Sciences Inc (NASDAQ: ACHV) was given a new $6.00 price target on by analysts at Maxim Group. They now have a "buy" rating on the stock. 7.3%
7/25 Form S-1 ACHIEVE LIFE SCIENCES, 5.7%
8/8 Form EFFECT ACHIEVE LIFE SCIENCES, 5.7%
12/26 Form SC 13G ACHIEVE LIFE SCIENCES, Filed by: CVI Investments, Inc. 5.7%
12/18 Form EFFECT ACHIEVE LIFE SCIENCES, 4.4%
12/9 Achieve Life Sciences Announces Completion of Meeting with the U.S. Food & Drug Administration (FDA) on Cytisinicline Smoking Cessation Phase 3 Clinical Development Program 14.3%
5/28 Form 4 ACHIEVE LIFE SCIENCES, For: May 23 Filed by: Stewart Richard Alistair 11.6%
6/11 Achieve Life Sciences Inc (NASDAQ: ACHV) had its "buy" rating re-affirmed by analysts at LADENBURG THALM/SH SH. They now have a $20.00 price target on the stock, up previously from $12.00. 9.2%
6/7 Form 3 ACHIEVE LIFE SCIENCES, For: May 30 Filed by: Armistice Capital Master Fund Ltd. 8.4%
8/12 Achieve Life Sciences Inc (NASDAQ: ACHV) was given a new $6.00 price target on by analysts at Maxim Group. They now have a "buy" rating on the stock. 7.3%
7/25 Form S-1 ACHIEVE LIFE SCIENCES, 5.7%
8/8 Form EFFECT ACHIEVE LIFE SCIENCES, 5.7%
12/26 Form SC 13G ACHIEVE LIFE SCIENCES, Filed by: CVI Investments, Inc. 5.7%
12/18 Form EFFECT ACHIEVE LIFE SCIENCES, 4.4%
TOP News Decliners
12/17
Achieve Life Sciences Announces Pricing of $12 Million Underwritten Public Offering
-54.0%
3/13 Achieve Life Sciences EPS beats by $0.02 [Seeking Alpha] -21.8%
6/11 Achieve Life Sciences Announces Statistically Significant Improvement in Quit Rates for Simplified Cytisinicline Dosing Schedule in Phase 2b ORCA-1 Dose-Selection Trial -21.4%
11/6 Form S-1 ACHIEVE LIFE SCIENCES, -19.2%
3/12 Achieve Life Sciences Announces Presentation of Additional Cytisinicline Analyses at the Society for Research on Nicotine & Tobacco (SRNT) Annual Meeting -16.1%
12/16 Form S-1/A ACHIEVE LIFE SCIENCES, -11.3%
12/23 Here's Why We're A Bit Worried About Achieve Life Sciences's (NASDAQ:ACHV) Cash Burn Situation [Yahoo! Finance News] -10.3%
9/30 Achieve Life Sciences Announces Completion of Maximum Tolerated Dose Study -9.6%
5/15 Achieve Reports Financial Results for First Quarter 2019 and Provides Cytisinicline Clinical Development Update -9.2%
2/6 Achieve Life Sciences Announces Agreement with the FreeMind Group to Assist in Securing Non-Dilutive Funding to Evaluate Cytisinicline in Vaping and e-Cigarette Users -8.6%
3/13 Achieve Life Sciences EPS beats by $0.02 [Seeking Alpha] -21.8%
6/11 Achieve Life Sciences Announces Statistically Significant Improvement in Quit Rates for Simplified Cytisinicline Dosing Schedule in Phase 2b ORCA-1 Dose-Selection Trial -21.4%
11/6 Form S-1 ACHIEVE LIFE SCIENCES, -19.2%
3/12 Achieve Life Sciences Announces Presentation of Additional Cytisinicline Analyses at the Society for Research on Nicotine & Tobacco (SRNT) Annual Meeting -16.1%
12/16 Form S-1/A ACHIEVE LIFE SCIENCES, -11.3%
12/23 Here's Why We're A Bit Worried About Achieve Life Sciences's (NASDAQ:ACHV) Cash Burn Situation [Yahoo! Finance News] -10.3%
9/30 Achieve Life Sciences Announces Completion of Maximum Tolerated Dose Study -9.6%
5/15 Achieve Reports Financial Results for First Quarter 2019 and Provides Cytisinicline Clinical Development Update -9.2%
2/6 Achieve Life Sciences Announces Agreement with the FreeMind Group to Assist in Securing Non-Dilutive Funding to Evaluate Cytisinicline in Vaping and e-Cigarette Users -8.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: